medicare coverage for glp 1 Bridge Program Explained: GLP-1 Medications Weight Loss Medicare GLP-1 Bridge Program 2026:
Description
Shen C, Wu X, Xu C et al
Wright Currently approved GLP-1 receptor agonists for treating type 2 diabetes and, in some cases, obesity, include dulaglutide (Trulicity, Eli Lilly & Co.), exenatide (Byetta, Amylin Pharmaceuticals
They're usually injected and come with high price tags (up to $1,000/month) and a long list of potential side effects, from nausea and bloating to more serious risks like pancreatitis, bone-density loss, and even tumors
Gentle GLP-1 support at micro doses
Regular thyroid screening is recommended for such patients
